Dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin are vital second-line or monotherapy anti-hyperglycemia drugs, decreasing plasma DPP-4 activity by 80% and elevating active glucagon-like peptide-1 levels, thus enhancing cell functionality [13,14]. Here, DPP4 is linked to Hyperglycemia.